Preferential PDE4B Inhibition - A Step toward a New Treatment for Idiopathic Pulmonary Fibrosis

N Engl J Med. 2022 Jun 9;386(23):2235-2236. doi: 10.1056/NEJMe2205411.

Author

Rachel C Chambers¹

Affiliation

¹ From the Centre for Inflammation and Tissue Repair (UCL Respiratory), Division of Medicine, University College London, London.

PMID: 35675182
DOI: 10.1056/NEJMe2205411

No abstract available

Publication types

Editorial
Comment

MeSH terms

Cyclic Nucleotide Phosphodiesterases, Type 4
Humans
Idiopathic Pulmonary Fibrosis* / drug therapy
Phosphodiesterase 4 Inhibitors* / therapeutic use

Substances

Phosphodiesterase 4 Inhibitors
Cyclic Nucleotide Phosphodiesterases, Type 4
PDE4B protein, human